Zhang, Wenbo
Ross, P. Joel http://orcid.org/0000-0001-7105-7117
Ellis, James http://orcid.org/0000-0002-4400-0091
Salter, Michael W. http://orcid.org/0000-0001-6897-6585
Funding for this research was provided by:
Gouvernement du Canada | Canadian Institutes of Health Research (FDN-154336, MOP-133423, EPS-129129, MOP-133423)
Article History
Received: 3 February 2022
Revised: 25 May 2022
Accepted: 27 May 2022
First Online: 9 June 2022
Competing interests
: M.W.S. is a founder, shareholder and Board member of NoNO Inc, which is developing Tat-NR2B9c, now known as nerinetide, as a therapeutic agent. All other authors report no biomedical financial interests or potential conflict of interest.